Lonza has entered an agreement to purchase a sterile drug product fill & finish facility from Novartis. The closing is expected to take place within the coming months. The new facility, in Stein, Switzerland will enable Lonza Pharma & Biotech to build on existing parenteral drug product development and testing capabilities and offer an end-to-end service to its customers for clinical supply and launch. It will be the first sterile drug product fill and finish facility in Lonza’s network....